10.1002/cbic.202000661 36 LeeJ.RohJ.-L
Food and Drug Administration (2025) Highlights of prescribing information, WEGOVY (semaglutide) injection, for subcutaneous use, FDA (2025) Highlights of prescribing information, RYBELSUS (semaglutide) tablets, for oral use, FDA (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Interactions with Other Medications : Semaglutide may interact with other medications, particularly certain oral drugs
Post-MI cardiac protection Dosage (Adults) Starting dose: 2550 mg once daily Maintenance: 50100 mg/day (once or twice daily) Dose adjustments in liver impairment Side Effects Generally well tolerated
no new patients could be initiated on funded dulaglutide or liraglutide
Originally approved to treat type 2 diabetes, its now one of the most effective medications for long-term weight reduction